The wait is over. On June 30, 2026, the FDA issued modified-risk granted orders for 20 Zyn nicotine pouch products, clearing the brand to tell adult smokers — in plain language — that switching to Zyn lowers their risk of several serious smoking-related diseases. It's the first time any nicotine pouch has been authorized to make a reduced-risk claim.
What happened
The FDA authorized Swedish Match USA, Inc. — a Philip Morris International subsidiary — to market 20 Zyn products with a specific claim: "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis." The orders cover ten flavors — Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint and Wintergreen — each in 3mg and 6mg strengths. These are the same pouches that already cleared FDA premarket review back in January 2025; the new decision is about what Zyn can say, not whether it can be sold.
The agency said its scientists concluded the claim is "scientifically accurate" for these products, that consumers understand it, and that marketing with the claim would benefit public health overall. The FDA also weighed data on youth use and recommendations from a January 22, 2026 advisory committee meeting. The orders come with strings: Swedish Match must run postmarket surveillance, and the authorizations expire in five years — and can be pulled early if youth uptake spikes.
Why it matters
This is a milestone for the fastest-growing category in nicotine. Zyn already dominates the U.S. pouch market, but it has never been allowed to advertise itself as lower-risk. An MRTP authorization changes the sales pitch, letting the brand speak directly to adult smokers about switching — the first regulator-blessed "reduced risk" messaging in the pouch aisle. It also reinforces a broader theme: the FDA continues to draw a line between combustible cigarettes and smoke-free alternatives.
What this means for pouch and vape users
If you use pouches or you're weighing a switch away from cigarettes, expect clearer, FDA-sanctioned language about relative risk showing up on Zyn packaging and marketing. But read the fine print the FDA itself printed: "lower risk" is not "safe." The agency was blunt that there's no safe tobacco product, that fully quitting is what most benefits health, and that pouches still deliver nicotine and remain strictly for adults 21+. For the category as a whole, this decision likely accelerates attention on pouches — and invites scrutiny over keeping them away from teens.
"Today's decision allows these products to be marketed with a modified risk claim that informs adults who smoke about the lower risks associated with these products," said Bret Koplow, acting director of the FDA's Center for Tobacco Products.
The bottom line
The FDA just handed Zyn something no nicotine pouch has ever had: permission to say it's lower-risk than cigarettes. It's a real shift in how smoke-free nicotine gets sold in America — but the "lower-risk, not risk-free, adults-only" caveats travel with it. Watch for competitors to line up their own MRTP applications next.
This article covers a tobacco-regulation decision and is general information, not health advice. JellyPuffs sells nicotine products intended for adults 21+ only; there is no safe tobacco product.
